Table 3. Adverse events.

N, number of participants in dose group.

Number (%) of participants experiencing an adverse event	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
	N = 23	N = 62	N = 55	N = 62
Any adverse event	11 (47.8)	20 (32.3)	11 (20.0)	18 (29.0)
Adverse events reported by >5% subjects in any group
Dizziness	2 (8.7)	1 (1.6)	0	0
Insomnia	2 (8.7)	1 (1.6)	1 (1.8)	4 (6.5)
Any adverse event grade 3 or higher	1 (4.3)	2 (3.2)	4 (7.3)	5 (8.1)
Any adverse event leading to discontinuation of study drug	0	1 (1.6)	1 (1.8)	1 (1.6)
Any adverse event related to study drug	4 (17.4)	13 (21.0)	1 (1.8)	8 (12.9)
Any serious adverse event	0	2 (3.2)	1 (1.8)	1 (1.6)
Any adverse event leading to death	0	0	0	1 (1.6)*

*The subject had an adverse event of hypoxia that led to death. This occurred 31 days after discontinuation from the study after completion of study assessments and was not recorded in the study database but was recorded in the safety database.